Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pharmacokinetic study of the interaction between celecoxib and anticonvulsant drugs [phenytoin, carbamazepine, phenobarbital, primidone, gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide, felbamate, oxcarbazepine] in patients with newly diagnosed glioblastoma multiforme undergoing radiation therapy.

Trial Profile

A pharmacokinetic study of the interaction between celecoxib and anticonvulsant drugs [phenytoin, carbamazepine, phenobarbital, primidone, gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide, felbamate, oxcarbazepine] in patients with newly diagnosed glioblastoma multiforme undergoing radiation therapy.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Carbamazepine; Felbamate; Gabapentin; Lamotrigine; Levetiracetam; Oxcarbazepine; Phenobarbital; Phenytoin; Primidone; Tiagabine; Topiramate; Valproic acid; Zonisamide
  • Indications Glioblastoma
  • Focus Pharmacokinetics

Most Recent Events

  • 02 May 2012 Actual patient number is 35 according to ClinicalTrials.gov.
  • 18 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top